SLC32A1 and Alzheimer disease: On the contrary, 12A12mAb delivery appeared to be ineffective in balancing the intensity of vGAT, a GABAergic marker found to be slightly increased in Tg2576 AD animals (*p < 0.05), because no significant difference was found when the untreated transgenic group was compared to its antibody-treated counterpart (n.s. = not significant).